ISB Assistant Professor Dr. Sid Venkatesh is the co-first author of a paper in the journal Science. While at Washington University in St. Louis, Venkatesh and colleagues identified a novel gut microbial enzyme that impacts satiety-related signaling pathways in undernourished children treated with microbiota-directed complementary foods.
Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.
Netflix’s “Hack Your Health: The Secrets of Your Gut” is a documentary that merged gut microbiome experts, four individuals – including a well-known hot dog eating champion – facing personal battles with gastrointestinal health, and a unique, effective visual method of “showing” the gut microbiome in action.
ISB researchers have developed a novel way to simulate personalized, microbiome-mediated responses to diet. They use a microbial community-scale metabolic modeling (MCMM) approach to predict individual-specific short-chain fatty acid production rates in response to different dietary, prebiotic, and probiotic inputs.
Dr. Sean Gibbons is creating a new precision nutrition platform called My Digital Gut that leverages the gut microbiome to make nutrition and healthcare personalized, predictive, and preventive. In an ISB Research Roundtable presentation, Gibbons spoke about My Digital Gut and other microbiome-related projects studied in his lab.
Dr. Sid Venkatesh recently joined ISB as assistant professor and is our newest faculty member. In this Q&A, Venkatesh discusses his research, his aspirations in the gut-microbiota field, his philosophy as a scientist, what he does when he’s not in the lab, and more.
ISB Associate Professor Dr. Sean Gibbons was named a Highly Cited Researcher for 2023. It is the second consecutive year Gibbons has earned the distinction. The Highly Cited Research list is generated annually by Clarivate, which says: “Of the world’s population of scientists and social scientists, Highly Cited Researchers are 1 in 1,000.”
Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…
ISB Assistant Professor Dr. Sean Gibbons talked about the science behind statins in our most recent Research Roundtable virtual presentation. His talk was titled “Bugs vs. Drugs: How Our Unique Gut Microbiomes Shape Our Personalized Responses to Statins.”
New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.
The strongest associations with weight loss success or failure – independent of BMI – are found in the genetic capacity of the gut microbiome. These new findings open the door to diagnostic tests that can identify people likely to lose weight with healthy lifestyle changes and those who might need more drastic interventions.
In ISB’s first-ever Research Roundtable event, Assistant Professor Dr. Sean Gibbons delivered a presentation titled “Gut-Check: Personalized Nutrition and Your Microbiome.” His talk covered a lot of ground, including recently published research showing how the health of our microbiomes can predict longevity, and how we can build and maintain a healthy gut microbiome.
The gut microbiome is an integral component of the body, but its importance in the human aging process is unclear. ISB researchers and their collaborators have identified distinct signatures in the gut microbiome that are associated with either healthy or unhealthy aging trajectories, which in turn predict survival in a population of older individuals.
ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.
ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.
There is a dichotomy between Bacteroides- and Prevotella-dominated guts — two common gut bacterial genera — and there is a significant barrier when it comes to transitioning from one to the other.
A promising new open-source metabolic modeling tool provides microbiome researchers a path forward in predicting ecosystem function from community structure. News of the software package, called MICOM, was developed in part by researchers in ISB’s Gibbons Lab, and its uses were published in the journal mSystems.
